Literature DB >> 11072609

How and why should we detect ANCA?

M Segelmark1, K Westman, J Wieslander.   

Abstract

Antineutrophil cytoplasmic antibodies (ANCA) have become an established tool for the diagnosis of systemic vasculitis. The major role for ANCA testing is in diagnosing renal insufficiency of unknown origin, where a positive test indicates whether the patient will benefit from immunosuppressive treatment or not. A negative test result almost completely rules out the presence of systemic vasculitis. In this clinical setting the major antigens for ANCA are proteinase 3 and myeloperoxidase, and antibodies to these antigens can best be tested by ELISA. In other clinical settings like inflammatory bowel disease, arthritis and so on, several other ANCA specificities have been described and the IIF test is preferred. However, the clinical value of these somewhat more esoteric specificities is doubtful. New developments in assay techniques and better knowledge of specific epitopes will lead to tools for the improved diagnosis as well as follow up of patients during treatment, as has already been seen with the capture assay for PR3-ANCA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11072609

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  8 in total

Review 1.  Methods for the detection of anti-neutrophil cytoplasmic antibodies. Recommendations for clinical use of ANCA serology and laboratory efforts to optimize the informative value of ANCA test results.

Authors:  A Wiik
Journal:  Springer Semin Immunopathol       Date:  2001

2.  The effect of a symptom related "gating policy" on ANCA requests in routine clinical practice.

Authors:  D Sinclair; M Saas; J M Stevens
Journal:  J Clin Pathol       Date:  2004-02       Impact factor: 3.411

Review 3.  Antineutrophil cytoplasmic autoantibodies: how are they detected and what is their use for diagnosis, classification and follow-up?

Authors:  Jan Willem Cohen Tervaert; Jan Damoiseaux
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

4.  Increased circulating levels of proteinase 3 in patients with anti-neutrophilic cytoplasmic autoantibodies-associated systemic vasculitis in remission.

Authors:  S Ohlsson; J Wieslander; M Segelmark
Journal:  Clin Exp Immunol       Date:  2003-03       Impact factor: 4.330

Review 5.  Antineutrophil cytoplasmic autoantibodies: how should the biologist manage them?

Authors:  C Beauvillain; Y Delneste; G Renier; P Jeannin; J F Subra; A Chevailler
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

Review 6.  Autoantibodies in vasculitis.

Authors:  Allan Wiik
Journal:  Arthritis Res Ther       Date:  2003-04-09       Impact factor: 5.156

7.  Monocyte chemoattractant protein 1 is a prognostic marker in ANCA-associated small vessel vasculitis.

Authors:  Sophie Ohlsson; Omran Bakoush; Jan Tencer; Ole Torffvit; Mårten Segelmark
Journal:  Mediators Inflamm       Date:  2009-07-05       Impact factor: 4.711

8.  Circulating cytokine profile in anti-neutrophilic cytoplasmatic autoantibody-associated vasculitis: prediction of outcome?

Authors:  Sophie Ohlsson; Jörgen Wieslander; Mårten Segelmark
Journal:  Mediators Inflamm       Date:  2004-08       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.